MUSC Hollings 癌症中心与 Hess 和 Mehrotra 合作，第一位接受纯化 CAR-T 细胞治疗的边缘区淋巴瘤患者在家中康复。 First patient with marginal zone lymphoma to receive purified CAR-T cells in trial at MUSC Hollings Cancer Center, in partnership with Hess and Mehrotra, recovering at home.
第一位接受 MUSC Hollings 癌症中心制造的纯化 CAR-T 细胞的患者在参加临床试验后正在家中康复。 The first patient to receive purified CAR-T cells manufactured at MUSC Hollings Cancer Center is recovering at home after participating in a clinical trial. 该治疗由医学博士 Brian Hess 和博士 Shikhar Mehrotra 合作进行，有望比市场上的商业 CAR-T 细胞副作用更少、效果更持久。 The treatment, carried out in partnership by Brian Hess, M.D., and Shikhar Mehrotra, Ph.D., is hoped to have fewer side effects and longer-lasting results than commercial CAR-T cells on the market. 患者 Ted Kopacko 患有边缘区淋巴瘤 11 年，他希望这种治疗能够减轻他对维持药物的依赖。 The patient, Ted Kopacko, who has lived with marginal zone lymphoma for 11 years, hopes this treatment will alleviate his dependence on maintenance drugs.